Pulmonary arterial hypertension: Baseline characteristics from the REVEAL registry

Chest

Volumn 137, Issue 2, 2010, Pages 376-387

  Badesch, David B ^a   Raskob, Gary E ^b   Elliott, C Greg ^c   Krichman, Abby M ^d   Farber, Harrison W ^e   Frost, Adaani E ^f   Barst, Robyn J ^g   Benza, Raymond L ^h   Liou, Theodore G ⁱ   Turner, Michelle ^j   Giles, Scott ^k   Feldkircher, Kathy ^k   Miller, Dave P ^j   McGoon, Michael D ^l  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g Columbia University ^*  (United States)

^h ALLEGHENY GENERAL HOSPITAL   (United States)

ⁱ UNIVERSITY OF UTAH   (United States)

^j ICON CLINICAL RESEARCH   (United States)

^k Actelion Pharmaceuticals US Inc   (United States)

^l MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMBRISENTAN; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CORTICOSTEROID DERIVATIVE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; OXYGEN; PROSTACYCLIN; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST; VASODILATOR AGENT; WARFARIN;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; FEMALE; HEART CATHETERIZATION; HUMAN; HYPERTENSION; KIDNEY FAILURE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; SLEEP APNEA SYNDROME; WORLD HEALTH ORGANIZATION;

EID: 76749135710     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-1140     Document Type: Article

References (41)

1. McGoon M, Gutterman D, Steen V, et al; American College of Chest Physicians. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126(1 suppl):14S-34S.
2. Rubin LJ; American College of Chest Physicians. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126(1 suppl):4S-6S.
3. Rubin LJ, Badesch DB. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med. 2005;143(4):282-292.
4. McLaughlin VV, Presberg KW, Doyle RL, et al; American College of Chest Physicians. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126(1 suppl):78S-92S.
5. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107(2):216-223.
6. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343-349.
7. Badesch DB, Abman SH, Ahearn GS, et al;American College of Chest Physicians. Medical therapy for pulmonary arterial hypertension:ACCP evidence-based clinical practice guidelines. Chest. 2004;126(1 suppl):35S-62S.
8. GalièN, Torbicki A, Barst R, et al; Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J. 2004;25(24):2243-2278.
9. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension:updated ACCP evidence-based clinical practice guidelines. Chest. 2007;131(6):1917-1928.
10. Barst RJ, Rubin LJ, Long WA, et al; The Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296-302.
11. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132(6):425-434.
12. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358(9288):1119-1123.
13. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896-903.
14. Simonneau G, Barst RJ, Galie N, et al; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800-804.
15. Olschewski H, Simonneau G, GalièN, et al; Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322-329.
16. Barst RJ, Langleben D, Frost A, et al; STRIDE-1 Study Group. Sitaxsentan therapy for pulmonary arterial hypertension . Am J Respir Crit Care Med. 2004;169(4):441-447.
17. Barst RJ, Langleben D, Badesch D, et al; STRIDE-2 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006;47(10):2049-2056.
18. GaliéN, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46(3):529-535.
19. GalièN, Ghofrani HA, Torbicki A, et al; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148- 2157.
20. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351(16):1655-1665.
21. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425-1436.
22. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006;114(13):1417-1431.
23. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023-1030.
24. Rich S, Rubin L, Walker AM, Schneeweiss S, Abenhaim L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest. 2000;117(3):870-874.
25. Walker AM, Langleben D, Korelitz JJ, et al. Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J. 2006;152(3):521-526.
26. McGoon MD, Krichman A, Farber HW, et al. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc. 2008;83(8):923-931.
27. Simonneau G, GalièN, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(12 suppl S):5S-12S.
28. Wysowski DK, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States,1982-1992. Obstet Gynecol. 1995;85(1):6-10.
29. Brett KM, Madans JH. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiol. 1997;145(6):536-545.
30. Badesch DB, Wynne KM, Bonvallet S, Voelkel NF, Ridgway C, Groves BM. Hypothyroidism and primary pulmonary hypertension: an autoimmune pathogenetic link? Ann Intern Med. 1993;119(1):44-46.
31. Curnock AL, Dweik RA, Higgins BH, Saadi HF, Arroliga AC. High prevalence of hypothyroidism in patients with primary pulmonary hypertension. Am J Med Sci. 1999;318(5):289-292.
32. Arroliga AC, Dweik RA, Rafanan AL. Primary pulmonary hypertension and thyroid disease. Chest. 2000;118(4):1224-1225.
33. Kashyap AS, Kashyap S. Thyroid disease and primary pulmonary hypertension. JAMA. 2001;285(22):2853-2854.
34. Marvisi M, Brianti M, Marani G, Del Borello R, Bortesi ML, Guariglia A. Hyperthyroidism and pulmonary hypertension. Respir Med. 2002;96(4):215-220.
35. Chu JW, Kao PN, Faul JL, Doyle RL. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest. 2002;122(5):1668-1673.
36. Simonneau G, Rubin LJ, GalièN, et al; PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149(8):521-530.
37. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174(11):1257-1263.
38. Barst RJ, Ivy D, Badesch DB, et al. REVEAL registry:pediatric IPAH versus pediatric pulmonary vascular disease associated with congenital heart disease [abstract]. J Heart Lung Trans. 2009;28(2):S203.
39. Barst RJ, Ivy D, Badesch DB, et al. REVEAL registry: comparison of patients with childhood-onset and adult-onset pulmonary vascular disease associated with congenital heart disease [abstract]. J Heart Lung Trans. 2009;28(2):S312.
40. Barst RJ, Ivy D, Badesch DB, et al. REVEAL registry: comparison of patients with childhood-onset and adult-onset idiopathic pulmonary arterial hypertension [abstract]. J Heart Lung Trans. 2009;28(2):S146.
41. Frost AE, Badesch DB, Barst RJ, et al. A comparison of REVEAL registry demographic data with other/prior registries of pulmonary arterial hypertension(PAH) [abstract]. Chest. 2008;134(4):134001S.